While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

A novel pilot study, the TRIMM trial, is investigating if a GLP-1 agonist can eliminate minimal residual disease (MRD), as measured by ctDNA, in breast cancer patients with obesity. This frames a metabolic intervention as a potential anti-cancer therapeutic, moving beyond its role in supportive care.

To prevent rebound weight gain and associated inflammation—which is particularly detrimental for cancer survivors—patients should not stop GLP-1s abruptly. Instead, a slow, methodical 20-week taper is recommended, with close monitoring to ensure weight stability before full discontinuation.

When stopping GLP-1 drugs like Ozempic, hunger doesn't just return to normal; it comes back with a "ferocious, animalistic" vengeance that is far more intense than before starting the medication. This powerful rebound effect is a primary driver of rapid weight regain.

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

Beyond weight management, preliminary evidence suggests GLP-1 agonists may help with vasomotor symptoms (hot flashes) and arthralgia (joint pain). The proposed mechanism is indirect, likely through reduced inflammation from fat loss and less mechanical load on joints, representing a novel potential benefit for patients.

Patients often worry that anti-estrogen therapies directly cause weight gain. However, the mechanism is more nuanced: the drugs induce a postmenopausal state characterized by inflammation and metabolic dysfunction, which, combined with natural aging, makes weight gain more likely and weight loss more difficult.

Unpublished data from a UT Southwestern group indicates that using GLP-1 agonists during a specific neoadjuvant chemo-immunotherapy regimen (Keynote 522) may significantly reduce pathologic complete response rates. This critical safety concern is prompting forthcoming ESMO guidelines recommending against their concurrent use.

The obesity market is evolving beyond maximum weight loss. Key differentiators will become dosing convenience, side effect profiles, and preserving lean muscle. This creates space for novel mechanisms, potentially as add-on therapies to lower GLP-1 doses and mitigate side effects.